Premium
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer
Author(s) -
Kristiansen Glen,
Pilarsky Christian,
Pervan Janja,
Stürzebecher Burkhard,
Stephan Carsten,
Jung Klaus,
Loening Stefan,
Rosenthal Andre,
Dietel Manfred
Publication year - 2003
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10324
Subject(s) - prostate cancer , medicine , cd24 , prostate , oncology , proportional hazards model , grading (engineering) , lymph node , pca3 , survival analysis , pathology , cancer , cancer stem cell , biology , ecology
Abstract BACKGROUND The prognostic impact of tumor grading and staging is markedly reduced in organ confined or moderately differentiated prostate cancer, which underscores the importance of new prognostic markers. Evaluating public expression data of prostate cancer, we found an upregulation of the candidate gene CD24 . METHODS We examined immunohistochemically the expression of CD24 protein in 31 nodal metastases and 102 adenocarcinomas of the prostate and correlated our findings to clinicopathological parameters. RESULTS CD24 expression was found in 48% of primary prostate cancer cases and in 68% of lymph node metastases. Kaplan Meier curves and Cox regression analysis showed that CD24 expression was strongly linked to significantly earlier disease progression (relative risk = 3.2), which was especially pronounced in organ confined, or moderately differentiated primary prostate tumors. CONCLUSIONS We conclude that CD24 is an important prognostic tissue marker for prostate cancer which could help to define patients of low or high risk of recurrence. © 2003 Wiley‐Liss, Inc.